Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00102687
Status:
COMPLETED
Last Update Posted:
2019-11-22
First Post:
2005-01-31
Brief Title:
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
A Multicenter Randomized Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if azacitidine combined with Best Supportive Care BSC is effective in treating myelodysplastic syndromes MDS when given according to a different doses and dosing schedules
Detailed Description:
ComparisonControl Interventions The comparison is azacitidine at different doses and schedules
Duration of Intervention Treatment lasted for a maximum of 18 cycles which is up to 24 months
Duration of Intervention Treatment lasted for a maximum of 18 cycles which is up to 24 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None